Casetta, C.
Santosh, P.
Bayley, R.
Bisson, J.
Byford, S.
Dixon, C.
Drake, R. J.
Elvins, R.
Emsley, R.
Fung, N.
Hayes, D.
Howes, O.
James, A.
James, K.
Jones, R.
Killaspy, H.
Lennox, B.
Marchant, L.
McGuire, P.
Oloyede, E.
Rogdaki, M.
Upthegrove, R.
Walters, J.
Egerton, A.
MacCabe, J. H.
Funding for this research was provided by:
NIHR (NIHR131175, NIHR131175, NIHR131175, NIHR131175, NIHR131175, NIHR131175, NIHR131175, NIHR131175, NIHR131175, NIHR131175, NIHR131175, NIHR131175, NIHR131175, NIHR150308, NIHR131175)
Article History
Received: 4 October 2023
Accepted: 22 November 2023
First Online: 14 February 2024
Declarations
:
: The trial will be conducted in compliance with the principles of the Declaration of Helsinki (1996), the principles of GCP and in accordance with all applicable regulatory requirements including but not limited to the Research Governance Framework and the Medicines for Human Use (Clinical Trial) Regulations 2004, as amended in 2006 and any subsequent amendments. The trial has been approved by London—Dulwich Research Ethics Committee (REC reference: 22/LO/0723) and obtained Clinical Trial Authorisation (CTA) from the Medicines & Healthcare products Regulatory Agency (MHRA; CTA 22926/0007/001–0003). Informed consent will be obtained, according to GCP guidelines.
: Not applicable.
: The authors declare no competing interests.